Cure8 news brief
The study connects microbiome disruptions to new food intolerances in people with IBD in remission, which may explain persistent food-related symptoms despite controlled inflammation and could point to microbiome-based interventions in the future.
People with IBD who have new or worsening food reactions, clinicians and dietitians who manage IBD, and researchers studying the gut microbiome and food-immune interactions.
Researchers compared stool samples and self-reported food intolerances from people with IBD in remission and healthy controls, finding lower microbial diversity and reduced ability to break down some food proteins in participants with IBD—especially those who reported intolerances.
The investigators and independent clinicians describe this as early, proof-of-concept work and say more research is needed before clinical recommendations change.
The team is exploring whether restoring bacteria that metabolize specific food components (for example via probiotics) could reduce food-triggered immune reactions, but this is investigational and not yet a treatment option.
Practical steps clinicians and dietitians in the article recommend include tracking symptoms, testing for active inflammation and celiac disease before removing foods like gluten, and working with an IBD-focused dietitian to avoid unnecessary dietary restrictions.
This is early, proof-of-concept research linking stool microbiota differences and impaired breakdown of certain food proteins to self-reported intolerances. The article cautions against self-directed food elimination and notes that clinical applications (such as probiotics to restore specific bacteria) are still investigational.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The study suggests vitamin D might help the immune system tolerate gut bacteria better and lower intestinal inflammation, which could mean fewer symptoms or flares for people with Crohn’s disease or ulcerative colitis.
The study suggests that in some people with IBD who have Candida overgrowth, systemic antifungal therapy (fluconazole) can change gut microbes and metabolites in ways linked to better disease activity over 8 weeks. That...
The studies identify a metabolic reason why the inflamed gut struggles to heal: inflammation reduces an enzyme (QPRT) needed for NAD+ production, starving regenerating intestinal cells of energy. That suggests...
